Login
Who's Online
We have 119 guests and no members online
Statistics
- Users 5440
- Articles 715
- Articles View Hits 16515649
Advertisement Rates
We suggest a minimum of 3 months or at least 10,000 impressions, but please keep in mind that these rates and time lengths are not set in stone, but rather displayed to give you an idea on how our ad pricing is usually structured. By advertising on Gene Therapy Net, you agree to our terms and conditions listed below.
Contact us for more information about advertising.
Advertising Terms and Conditions: All ads are reviewed for correct usage, and must be approved prior to publication. Gene Therapy Net reserves the right to refuse advertising privileges to any web site for any reason, including the promotion of pornographic products and/or content, the advocating of illegal activities, immoral conduct, plagiarism, cheating, etc. Gene Therapy Net shall not be held responsible for grammatical errors, typographical errors, or errors in artwork provided by the advertiser. All ads are at the discretion of Gene Therapy Net. All rates are agreed on before advertisement is placed. Your ad will be place after full payment has been received. When an order has been received and payment taken for the service there will be no refund to the advertiser. Gene Therapy Net reserves the right to modify, change or otherwise improve upon the design and format of any or all of its pages at any time without notice. Gene Therapy Net reserves the right to modify, eradicate and/or change any or all of these terms and conditions without notice, including the right to change the above rates or to terminate this advertising program. We appreciate, but do not require, reciprocal links to Gene Therapy Net to be posted on your site.
Suggestions
Gene Therapy News
- FDA Approves First Gene Therapy to Treat Children with Metachromatic Leukodystrophy - JD Supra
Thu, 28 Mar 2024 17:52:4 GMT - Cell And Gene Therapy Manufacturing Services Market Set To - GlobeNewswire
Thu, 28 Mar 2024 16:31:4 GMT - Trial will test gene therapy for limb-girdle muscular dystrophy type - Muscular Dystrophy News
Thu, 28 Mar 2024 15:27:2 GMT - REGENXBIO reports promising gene therapy for eye disease - Investing.com
Thu, 28 Mar 2024 14:22:1 GMT - Cell therapy weekly: Clinical Trial Application Approval for Muscular Dystrophy Gene Therapy - RegMedNet
Thu, 28 Mar 2024 13:58:0 GMT - REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III - Genetic Engineering & Biotechnology News
Thu, 28 Mar 2024 12:05:1 GMT - Robots and AI: The Future of Cell and Gene Therapy Manufacturing - Genetic Engineering & Biotechnology News
Wed, 27 Mar 2024 17:00:2 GMT - Gene therapy offers hope for giant axonal neuropathy patients - UT Southwestern
Wed, 27 Mar 2024 16:52:2 GMT - Gene Therapy, DNA's Past, RNA's Future: Early History - Forbes
Wed, 27 Mar 2024 16:20:5 GMT - Nanoscope Claims Phase II Win for Gene Therapy After Changing Primary Endpoint - BioSpace
Wed, 27 Mar 2024 16:18:4 GMT - Atamyo's gene therapy for LGMD2C/R5 cleared to enter clinic in Europe - BioWorld Online
Wed, 27 Mar 2024 14:00:0 GMT - Intellia ending work with Regeneron on hemophilia B gene therapy - Hemophilia News Today
Wed, 27 Mar 2024 13:35:0 GMT - Atamyo obtains clearance for muscular dystrophy gene therapy trial in Europe - Clinical Trials Arena
Wed, 27 Mar 2024 12:26:4 GMT - Competitive Intelligence Insights: Cell & Gene Therapy - Evaluate Pharma
Wed, 27 Mar 2024 11:55:4 GMT - Gene therapy maker bluebird to revise financials after accounting errors - Reuters
Tue, 26 Mar 2024 15:55:0 GMT